<DOC>
	<DOCNO>NCT00641654</DOCNO>
	<brief_summary>To evaluate efficacy pegylated interferon alfa-2a 40 kD ( PEGASYS ) combination therapy ribavirin ( Copegus ) give 24 48 week patient chronic hepatitis C ( CHC ) virus infection genotype 2 3 respond ( i.e . HCV-RNA &lt; 50 IU/mL end previous therapy ) , relapse ( i.e . detectable HCV-RNA end prior treatment ) previous therapy pegylated interferon ribavirin give least 12 week 24 week .</brief_summary>
	<brief_title>Combination Therapy With Pegylated Interferon Ribavirin Patients With Chronic Hepatitis C Genotype 2 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon Ribavirin</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male female patient ≥ 18 year age Serologic evidence chronic hepatitis C infection antiHCV antibody test Serum HCVRNA ≥ 15 IU/mL . HCV genotype 2 or/and 3 infection confirm within past 6 month precede initiation test drug dosing . The HCV genotype must reconfirm termination previous treatment period Previous relapse ( i.e . HCVRNA &lt; 50 IU/mL end previous therapy ) one treatment period pegylated interferon alfa2a alfa2b combination therapy ribavirin least 12 week 24 week A minimum 24 week must elapse since last dose pegylated interferon ribavirin previous treatment period patient include study Compensated liver disease ( ChildPugh Grade A clinical classification ) Patients suspected cirrhosis transition cirrhosis must abdominal ultrasound , CT scan , MRI scan without evidence hepatocellular carcinoma serum AFP &lt; 100 ng/mL within 2 month randomization Negative urine blood pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose study drug All fertile male females receive ribavirin must use effective contraception treatment 6 month treatment end Having liver biopsy obtain within 5 year study encourage , optional accordance local treatment tradition . Women ongoing pregnancy breast feed Previous nonresponse treatment ( define detectable HCV RNA ≥ 50 IU/ml end previous treatment ) pegylated interferon alfa2a alfa2b combination therapy ribavirin least 12 week 24 week Less 24 week elapse since last dose pegylated interferon ribavirin previous treatment period prior inclusion study . Therapy systemic antiviral antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) ≤ 6 month prior first dose study drug Any investigational drug ≤ 6 week prior first dose study drug . HCV genotype 1 , 4 , 5 6 infection Positive test screen antiHAV IgM Ab HBsAg antiHBc IgM Ab antiHIV Ab Evidence medical condition associate chronic liver disease HCV ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure ) History evidence decompensated liver disease Neutrophil count &lt; 1500 cells/mm3 platelet count &lt; 75,000 cells/mm3 screen Serum creatinine level &gt; 2 mg/dl ( &gt; 124 µmol/L ) creatinine clearance &lt; 50 ml/minute screen Severe psychiatric disease , especially depression , judge treat physician History severe seizure disorder current anticonvulsant use History immunologically mediate disease severe chronic pulmonary disease associate functional limitation severe cardiac disease major organ transplantation evidence severe illness malignancy condition would make patient , opinion investigator , unsuitable study Thyroid dysfunction adequately control ( TSH T4 level normal range ) Evidence severe retinopathy ( e.g . CMV retinitis , macula degeneration ) clinically relevant ophthalmological disorder due diabetes mellitus hypertension Evidence drug abuse ( include excessive alcohol consumption ) accordance local therapeutic tradition . ( Patients receive Methadone Subutex therapy may include study . ) Inability unwillingness provide inform consent abide requirement study Male partner woman pregnant Hemoglobin &lt; 11.3 g/dL ( &lt; 7.0 mmol/L ) woman &lt; 12.9 g/dL ( &lt; 8.0 mmol/L ) men screen . Any patient increase baseline risk anemia ( e.g . thalassemia , spherocytosis , etc ) anemia would medically problematic Patients document presumed coronary artery disease cerebrovascular disease enrol , judgment investigator , acute decrease hemoglobin 4 g/dL ( may see ribavirin therapy ) would welltolerated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>genotype 2 3</keyword>
	<keyword>relapse</keyword>
	<keyword>pegylated interferon</keyword>
	<keyword>ribavirin</keyword>
</DOC>